23I Stock Overview
A biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Intra-Cellular Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$81.50 |
| 52 Week High | US$87.00 |
| 52 Week Low | US$53.90 |
| Beta | 0.97 |
| 11 Month Change | 14.79% |
| 3 Month Change | 25.38% |
| 1 Year Change | 47.38% |
| 33 Year Change | 140.13% |
| 5 Year Change | 810.61% |
| Change since IPO | 568.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 23I | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.9% | 1.2% | 1.3% |
| 1Y | 47.4% | -19.7% | 7.9% |
Return vs Industry: 23I exceeded the German Pharmaceuticals industry which returned -19% over the past year.
Return vs Market: 23I exceeded the German Market which returned 7.2% over the past year.
Price Volatility
| 23I volatility | |
|---|---|
| 23I Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 23I has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 23I's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 610 | Sharon Mates | www.intracellulartherapies.com |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications.
Intra-Cellular Therapies, Inc. Fundamentals Summary
| 23I fundamental statistics | |
|---|---|
| Market cap | €8.70b |
| Earnings (TTM) | -€81.84m |
| Revenue (TTM) | €581.51m |
15.0x
P/S Ratio-106.3x
P/E RatioIs 23I overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 23I income statement (TTM) | |
|---|---|
| Revenue | US$613.73m |
| Cost of Revenue | US$263.87m |
| Gross Profit | US$349.86m |
| Other Expenses | US$436.23m |
| Earnings | -US$86.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 57.01% |
| Net Profit Margin | -14.07% |
| Debt/Equity Ratio | 0% |
How did 23I perform over the long term?
See historical performance and comparison